Released Aug 5, 2021, after the close
10-Q filed Aug 5, 2021, 36 days after period end · 0001564590-21-041680
Q2 2021 · 10-Q
Revenue—
Net Income-$23.60M-$23.60M N/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$0.55-$0.55 N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$23,666,000N/M
Operating Cash Flowderived-$21,808,000N/M
Free Cash Flowderived-$21,808,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | — | $39.38M | $3.08M | $3.22M |
| Net Income | -$23.60M | $7.27M | -$18.50M | -$26.81M |
| EPS Diluted | -$0.55 | $0.19 | -$0.72 | -$1.30 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR